ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells
Open Access
- 1 December 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (12), 3739-3750
- https://doi.org/10.1158/1535-7163.mct-08-0548
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to prevent colorectal tumorigenesis. Although antitumor effects of NSAIDs are mainly due to inhibition of cyclooxygenase activity, there is increasing evidence that cyclooxygenase-independent mechanisms may also play an important role. The early growth response-1 (EGR-1) gene is a member of the immediate-early gene family and has been identified as a tumor suppressor gene. Tolfenamic acid is a NSAID that exhibits anticancer activity in a pancreatic cancer model. In the present study, we investigated the anticancer activity of tolfenamic acid in human colorectal cancer cells. Tolfenamic acid treatment inhibited cell growth and induced apoptosis as measured by caspase activity and bioelectric impedance. Tolfenamic acid induced EGR-1 expression at the transcription level, and analysis of the EGR-1 promoter showed that a putative ETS-binding site, located at −400 and −394 bp, was required for activation by tolfenamic acid. The electrophoretic mobility shift assay and chromatin immunoprecipitation assay confirmed that this sequence specifically bound to the ETS family protein epithelial-specific ETS-1 (ESE-1) transcription factor. Tolfenamic acid also facilitated translocation of endogenous and exogenous ESE-1 to the nucleus in colorectal cancer cells, and gene silencing using ESE-1 small interfering RNA attenuated tolfenamic acid-induced EGR-1 expression and apoptosis. Overexpression of EGR-1 increased apoptosis and decreased bioelectrical impedance, and silencing of endogenous EGR-1 prevented tolfenamic acid-induced apoptosis. These results show that activation of ESE-1 via enhanced nuclear translocation mediates tolfenamic acid-induced EGR-1 expression, which plays a critical role in the activation of apoptosis. [Mol Cancer Ther 2008;7(12):3739–50]Keywords
This publication has 44 references indexed in Scilit:
- Multiple mechanisms are involved in 6‐gingerol‐induced cell growth arrest and apoptosis in human colorectal cancer cellsMolecular Carcinogenesis, 2007
- Green tea catechin (−)-epicatechin gallate induces tumour suppressor protein ATF3 via EGR-1 activationEuropean Journal of Cancer, 2007
- Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell linesJournal of Translational Medicine, 2007
- Changes in gene expression contribute to cancer prevention by COX inhibitorsProgress in Lipid Research, 2006
- 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes Are Peroxisome Proliferator-Activated Receptor γ Agonists but Decrease HCT-116 Colon Cancer Cell Survival through Receptor-Independent Activation of Early Growth Response-1 and Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1Molecular Pharmacology, 2005
- Expression of NAG-1, a Transforming Growth Factor-β Superfamily Member, by Troglitazone Requires the Early Growth Response Gene EGR-1Published by Elsevier BV ,2004
- COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxibThe FASEB Journal, 2001
- EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicityOncogene, 2000
- A Novel ets-related Transcription Factor, ERT/ESX/ESE-1, Regulates Expression of the Transforming Growth Factor-β Type II ReceptorPublished by Elsevier BV ,1998
- Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formationInternational Journal of Cancer, 1997